KNSA
Kiniksa Pharmaceuticals Ltd
NASDAQ: KNSA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$52.99
-1.60% today
Updated 2026-04-29
Market cap
$4.08B
P/E ratio
58.23
P/S ratio
6.02x
EPS (TTM)
$0.91
Dividend yield
—
52W range
$25 – $54
Volume
0.8M
Kiniksa Pharmaceuticals Ltd (KNSA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
8.71%
Operating margin
9.78%
ROE
11.70%
ROA
7.18%
Debt/equity
0.02x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2016 | $0.00 | $-23.97M | — | — | — |
| 2017 | $0.00 | $-64.87M | — | — | — |
| 2018 | $0.00 | $-103.23M | — | — | — |
| 2019 | $0.00 | $-161.87M | — | — | — |
| 2020 | $7.70M | $-161.38M | -49.39% | -2,042.61% | -2,094.77% |
| 2021 | $38.54M | $-157.92M | 76.39% | -406.38% | -409.72% |
| 2022 | $220.18M | $183.36M | 89.60% | 4.44% | 83.28% |
| 2023 | $270.26M | $14.08M | 79.09% | -9.32% | 5.21% |
| 2024 | $423.24M | $-43.19M | 85.61% | -10.78% | -10.21% |
| 2025 | $677.56M | $59.01M | 54.63% | 11.40% | 8.71% |